Amelioration of diet-induced steatohepatitis in mice following combined therapy with ASO-Fsp27 and fenofibrate

Keyphrases

• Steatohepatitis 100%
• Antisense Oligonucleotides 100%
• Diet-induced 100%
• Fenofibrate 100%
• Combined Therapy 100%
• FSP27 100%
• Non-alcoholic Fatty Liver Disease (NAFLD) 80%
• Fat-specific Protein 27 40%
• C57BL 20%
• Liver 20%
• Hepatocellular Carcinoma 20%
• Disease Progression 20%
• Mouse Model 20%
• Liver Disease 20%
• Hepatocytes 20%
• Steatosis 20%
• Chronic Liver Disease 20%
• Hepatic Steatosis 20%
• Cirrhosis 20%
• Fibrosis 20%
• Obesity 20%
• Synergize 20%
• Therapeutic Potential 20%
• Targeted Treatment 20%
• PPAR Agonists 20%
• Hypertriglyceridemia 20%
• Treatment Course 20%
• Diet-induced Obesity 20%
• Trans Fat 20%
• Lipid Droplet-associated Proteins 20%
• Reduced Fat 20%
• Therapeutic Benefits 20%
• Triglyceride Accumulation 20%
• High Cholesterol 20%
• Hepatosteatosis 20%
• High-fructose Diet 20%
• Inflammation Oxidative Stress 20%
• Triglyceride Turnover 20%

Medicine and Dentistry

• Steatohepatitis 100%
• Antisense Oligonucleotide 100%
• Combined Therapy 100%
• Fenofibrate 100%
• Nonalcoholic Fatty Liver 80%
• Protein 40%
• Triacylglycerol 40%
• Fatty Liver 40%
• C57BL/6 20%
• Hepatocellular Carcinoma 20%
• Liver Disease 20%
• Targeted Therapy 20%
• Hepatocyte 20%
• Fibrosis 20%
• Steatosis 20%
• Chronic Liver Disease 20%
• Liver Cirrhosis 20%
• Oxidative Stress 20%
• Hypercholesterolemia 20%
• Peroxisome Proliferator Activated Receptor 20%
• Diet Induced Obesity 20%
• Hypertriglyceridemia 20%
• High-Fructose Diet 20%
• Peroxisome Proliferator Activated Receptor Agonist 20%
• Lipid Droplet Associated Protein 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Mouse 100%
• Antisense Oligonucleotide 100%
• Fenofibrate 100%
• Nonalcoholic Fatty Liver 80%
• Triacylglycerol 40%
• Protein 40%
• Fatty Liver 40%
• Liver Cell Carcinoma 20%
• C57BL 6 Mouse 20%
• Mouse Model 20%
• Inflammation 20%
• Steatosis 20%
• Liver Disease 20%
• Fibrosis 20%
• Liver Cirrhosis 20%
• Chronic Liver Disease 20%
• Peroxisome Proliferator Activated Receptor 20%
• Hypercholesterolemia 20%
• PPAR Agonist 20%
• Diet Induced Obesity 20%
• Fructose 20%
• Hypertriglyceridemia 20%
• Lipid Droplet Associated Protein 20%